Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combo in Advanced Non-squamous NSCLC Post-IO
NCT05738317Phase 2Unknown
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in non-small cell lung cancer (NSCLC). Primary endpoint: 6-month Progression-Free Survival Rate. Status: unknown.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05738317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738317.